Clever Culture Systems (ASX:CC5) said it received a second purchase order from an additional Bristol Myers Squibb facility for its Automated Plate Assessment System Independence technology, which is expected to form a case study for the potential roll out to other Bristol Myers Squibb sites, according to a Wednesday Australian bourse filing.
It said that the sales pipeline for the pharmaceutical industry consisted of over 40 active and qualified customer opportunities, representing an estimated AU$75 million in potential upfront sales revenue and AU$15 million per annum in recurring revenue.
A multinational pharmaceutical firm is evaluating its technology, which automates the imaging, analysis, and interpretation of microbiology culture plates, covering over 6,000 plates, with the resulting data currently being compiled. The evaluation assessed the performance of the settle plate analysis module and is being extended to the contact plate analysis module.
Its shares jumped 6% on market close on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。